{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-003512","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2024-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.732302+00:00","generated_at":"2026-06-07T00:52:35.010704+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"EyePoint doses first patient in Phase 2 VERONA trial of EYP-1901 for DME","bullets":["EYP-1901 (vorolanib/Durasert E) enters Phase 2 for diabetic macular edema; ~25 patients to be enrolled.","Primary endpoint: time to first supplemental aflibercept injection up to 24 weeks.","Topline data from VERONA expected in Q1 2025; PAVIA NPDR data due Q2 2024.","First Phase 3 pivotal trial in wet AMD anticipated to start in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-003512","json":"https://secwatch.observer/filing/0000950170-24-003512.json","markdown":"https://secwatch.observer/filing/0000950170-24-003512.md","text":"https://secwatch.observer/filing/0000950170-24-003512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024003512/0000950170-24-003512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024003512/eypt-20240110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T00:52:35.010704+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}